This is a purely administrative filing with no trading implications. Monitor the next quarterly filing for any updates on the STARLIGHT-1 clinical trial progress and cash runway, which are the key value drivers for this pre-revenue biotech.
Price Chart
Executive Summary
Estrella Immunopharma filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive compensation, security ownership, related transactions, and auditor fees) that was omitted from the original filing under General Instruction G(3). No financial statements were restated, no errors were corrected, and no material financial data was changed. The amendment is a routine administrative filing to complete the annual report.
Key Facts
- Amendment adds Part III (Items 10-14) disclosure only — no restatement or financial correction
- Auditor remains Macias Gini & O'Connell LLP; audit fees were $197,000 for FY2025 and $128,000 for the six-month transition period ended December 31, 2024
- CEO Cheng Liu and CFO Peter Xu each received $250,962 in salary for FY2025; no cash bonuses or new equity grants were awarded
- Controlling shareholder Eureka Therapeutics, Inc. beneficially owns 59.3% of outstanding common stock as of March 12, 2026
- Late Section 16(a) filings were reported: CFO Jiandong Xu filed one late Form 4 on April 29, 2026 for three purchases in September/October 2025; CEO Cheng Liu and CFO each filed late Form 4s on February 14, 2025 for October 2024 option grants
Financial Impact
No material financial impact — amendment adds governance and compensation disclosures only
Risk Factors
- Late Section 16(a) filings by CEO and CFO indicate potential insider trading compliance weaknesses
- Controlled company structure (59.3% ownership by Eureka) limits minority shareholder influence
- Pre-revenue biotech with no disclosed financial results in this amendment — cash burn and dilution risk remain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001213900-26-050433 |
| Document: ea028859101ex31-1.htm | 0001213900-26-050433 |
| Document: ea028859101ex31-2.htm | 0001213900-26-050433 |
| Document: 0001213900-26-050433-index-headers.html | 0001213900-26-050433 |
| Document: 0001213900-26-050433-index.html | 0001213900-26-050433 |
| Document: 0001213900-26-050433.txt | 0001213900-26-050433 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers